Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Apellis Pharmaceuticals ( (APLS) ) is now available.
On June 3, 2025, Apellis Pharmaceuticals held its Annual Meeting of Stockholders, where key decisions were made. A. Sinclair Dunlop, Alec Machiels, and Keli Walbert were elected as class II directors for a three-year term. Additionally, Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2025. The stockholders approved the executive compensation and recommended holding future advisory votes on executive compensation annually.
The most recent analyst rating on (APLS) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Apellis Pharmaceuticals stock, see the APLS Stock Forecast page.
Spark’s Take on APLS Stock
According to Spark, TipRanks’ AI Analyst, APLS is a Neutral.
Apellis Pharmaceuticals’ stock score reflects strong revenue growth and strategic FDA milestones tempered by ongoing profitability challenges and negative market momentum. The stock’s valuation is affected by its negative earnings, and while corporate governance improvements are positive, they do not significantly alter the current financial outlook.
To see Spark’s full report on APLS stock, click here.
More about Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on developing therapies for autoimmune and inflammatory diseases.
Average Trading Volume: 2,587,552
Technical Sentiment Signal: Sell
Current Market Cap: $2.41B
See more insights into APLS stock on TipRanks’ Stock Analysis page.